Trials / Terminated
TerminatedNCT03867370
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
A Phase Ib/II, Open-Label, Multi-Center Study Evaluating the Efficacy and Safety of Neoadjuvant Toripalimab Injection (JS001) or Toripalimab in Combination With Lenvatinib for Patients With Resectable Hepatocellular Carcinoma (HCC)
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate efficacy and safety of Toripalimab Injection (JS001) with or without Lenvatinib as a Neoadjuvant Therapy in patients with Resectable Hepatocellular Carcinoma (HCC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab (JS001 ) | Given IV |
| DRUG | Toripalimab (JS001 ) Lenvatinib | Given IV 4 mg capsules |
| DRUG | Toripalimab (JS001 ) Lenvatinib | Given IV 4 mg capsules |
Timeline
- Start date
- 2019-04-26
- Primary completion
- 2023-08-08
- Completion
- 2023-08-08
- First posted
- 2019-03-08
- Last updated
- 2023-11-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03867370. Inclusion in this directory is not an endorsement.